BPC-157 Protocol: Concentrations Behind the Schedule

A typical written protocol carries three fields: an amount, a frequency, and a duration. It rarely carries the fourth field, and the fourth is the one that makes the first field mean anything.

A vial arrives with a labelled dry mass. Common labels are 5 mg and 10 mg. Nothing in that vial can be measured by volume until liquid goes in, and the volume that goes in is a free choice made by whoever prepares it. Only after that does a graduation on a barrel correspond to a mass of peptide.

So a line reading "500 mcg" is complete only when it also reads "from a 10 mg vial reconstituted with 2 mL". Without the second half, the first half is a numerator with no denominator. Most published schedules stop at the numerator.

Concentration is mass divided by volume:

concentration = labelled mass / added volume

A 10 mg vial with 2 mL of bacteriostatic water gives 10 / 2 = 5 mg per mL. The same vial with 1 mL gives 10 / 1 = 10 mg per mL. The same vial with 5 mL gives 10 / 5 = 2 mg per mL. The powder never changed. The label never changed. Every draw from that vial changed fivefold between the first case and the third.

Running it the other way, from an intended volume to the mass inside it:

mass drawn = concentration x volume drawn

At 5 mg per mL, drawing 0.1 mL gives 5 x 0.1 = 0.5 mg, which is 500 mcg. At 10 mg per mL, that same 0.1 mL holds 1 mg, or 1000 mcg. Same syringe, same visible line, twice the material.

A U-100 insulin syringe is graduated so that 100 units fill 1 mL. One unit is therefore 0.01 mL. That is a volume, on every syringe of that type, always. It is never a mass, and no syringe knows what is dissolved in the liquid it holds.

The table below takes a single 5 mg vial and changes nothing except the water added.

Two things fall out of that table. The first is the fivefold spread already described. The second is the row that produces 12.5 units, which is not a readable graduation on a standard U-100 barrel. Reconstitution volume is worth choosing so that the masses you care about land on whole units rather than between them. That is a measurement decision, not a biological one, and it is the sort of thing a forum schedule never mentions.

Two assumptions sit under every row above, and both are worth stating plainly.

The first is that the syringe is a U-100. A U-40 syringe fills 1 mL at 40 units, so one unit is 0.025 mL, and every conversion in the table shifts. Reading a U-100 number off a U-40 barrel misreports the volume by a factor of 2.5 before any peptide is involved.

The second assumption is that the vial contains the mass printed on it. A label is a claim by the seller, not a measurement. Independent assay is the only thing that connects the two, and a compound sold as a research chemical carries no regulatory requirement that they match. All the arithmetic on this page is exact given an accurate label and inherits the label's error when the label is wrong.

Published efficacy work on BPC-157 is overwhelmingly rat work and cell culture work, much of it from a small number of research groups, covering tendon, ligament, muscle and gut outcomes. Those papers do specify amounts, and they specify them per kilogram of animal body weight along with a route and an injury model. That is a complete specification for a rat experiment. It is not convertible into a human figure by multiplying by a person's weight, because clearance, route and the injury models themselves do not carry across species.

Human trials do exist and are registered. Two can be named: [NCT07803250](https://clinicaltrials.gov/study/NCT07803250), a Phase 1 study in recovery after rotator cuff repair listed as not yet recruiting; and [NCT02637284](https://clinicaltrials.gov/study/NCT02637284), a Phase 1 safety and pharmacokinetics study with status listed as unknown. None has published efficacy results. Saying BPC-157 has no human trials is wrong. Saying human benefit has been shown is also wrong. Both statements fail, and both halves belong in any honest description.

BPC-157 holds no marketing authorisation from the FDA, the EMA or the MHRA. It is sold as a research chemical rather than a medicine.

Cost per mg is the one comparison that survives across vial sizes:

cost per mg = price paid / labelled mass

Take an assumed figure, since prices move and this page names no seller. A 5 mg vial bought at 40 currency units works out at 40 / 5 = 8 per mg. A 10 mg vial at 60 works out at 60 / 10 = 6 per mg. The larger vial is 25 per cent cheaper per mg despite costing more at checkout, which is the arithmetic that headline prices hide.

The same formula shows why the comparison is shallow on its own. It divides by the labelled mass, so a seller who overstates the label wins on paper. Cost per mg ranks sellers only within a set whose labels have been independently checked. Between an assayed vial and an unassayed one it compares nothing.

Concentration maths is exact and narrow. It tells you what is in a given volume once you know what went into the vial. It says nothing about whether the contents are what the label claims, whether they are pure, whether they are stable after reconstitution, or whether any of it does anything useful in a person. Those are separate questions, and three of the four are answered by assay rather than by calculation. The fourth waits on human trials that have not reported.